Nifty
:
10813.45
Sensex
:
36737.69
107.70 (1.01%)
408.68 (1.12%)
Nifty
Sensex
:
:
10813.45
36737.69
107.70 (1.01%)
408.68 (1.12%)

Alembic Pharmaceuticals Ltd.

Pharmaceuticals & Drugs - Global

Rating :
87/99

BSE: 533573 | NSE: APLLTD

NSE BSE
933.65
09-Jul-2020
  • Open
  • High
  • Low
  • Previous Close
  •  933.00
  •  959.00
  •  928.85
  •  931.10
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  334954
  •  3157.84
  •  983.15
  •  434.80

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 17,543.29
  • 21.17
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 19,210.04
  • 1.07%
  • 5.45

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 72.97%
  • 0.44%
  • 10.83%
  • FII
  • DII
  • Others
  • 7.3%
  • 6.90%
  • 1.56%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 14.38
  • 7.79
  • 13.74

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 23.85
  • 3.85
  • 14.56

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 25.52
  • 2.85
  • 25.36

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 20.10
  • 20.60
  • 20.50

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 6.11
  • 5.81
  • 4.30

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 14.68
  • 14.98
  • 14.14

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Var%
Dec 19
Dec 18
Var%
Sep 19
Sep 18
Var%
Jun 19
Jun 18
Var%
Net Sales
1,206.83
926.95
30.19%
1,209.13
1,018.15
18.76%
1,240.87
1,127.06
10.10%
948.91
862.53
10.01%
Expenses
879.31
748.91
17.41%
884.07
775.92
13.94%
895.35
824.72
8.56%
723.99
711.54
1.75%
EBITDA
327.52
178.04
83.96%
325.06
242.23
34.19%
345.52
302.34
14.28%
224.92
150.99
48.96%
EBIDTM
27.14%
19.21%
26.88%
23.79%
27.84%
26.83%
23.70%
17.51%
Other Income
0.89
3.37
-73.59%
0.41
3.52
-88.35%
0.36
2.37
-84.81%
3.29
0.10
3,190.00%
Interest
7.75
5.08
52.56%
7.36
5.95
23.70%
7.07
5.81
21.69%
4.98
1.57
217.20%
Depreciation
44.14
29.95
47.38%
41.82
29.05
43.96%
35.95
28.63
25.57%
35.40
27.60
28.26%
PBT
265.66
146.38
81.49%
276.29
210.75
31.10%
302.86
270.27
12.06%
155.04
121.92
27.17%
Tax
62.14
14.90
317.05%
48.60
40.00
21.50%
52.49
70.30
-25.33%
35.96
31.54
14.01%
PAT
203.52
131.48
54.79%
227.69
170.75
33.35%
250.37
199.97
25.20%
119.08
90.38
31.75%
PATM
16.86%
14.18%
18.83%
16.77%
20.18%
17.74%
12.55%
10.48%
EPS
10.80
6.98
54.73%
12.08
9.06
33.33%
13.28
10.61
25.16%
6.32
4.79
31.94%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Net Sales
-
4,605.76
3,934.68
3,130.18
3,134.61
3,165.99
2,056.13
1,863.22
1,520.35
1,465.41
1,202.05
Net Sales Growth
-
17.06%
25.70%
-0.14%
-0.99%
53.98%
10.35%
22.55%
3.75%
21.91%
 
Cost Of Goods Sold
-
1,039.38
992.70
885.56
887.57
823.95
639.85
627.02
609.56
637.39
534.07
Gross Profit
-
3,566.38
2,941.98
2,244.62
2,247.04
2,342.04
1,416.28
1,236.20
910.78
828.02
667.97
GP Margin
-
77.43%
74.77%
71.71%
71.68%
73.97%
68.88%
66.35%
59.91%
56.50%
55.57%
Total Expenditure
-
3,391.69
3,078.58
2,514.92
2,519.90
2,160.88
1,660.92
1,506.16
1,271.75
1,249.54
1,059.04
Power & Fuel Cost
-
102.40
88.86
70.35
64.20
58.89
43.31
32.07
26.66
29.57
24.58
% Of Sales
-
2.22%
2.26%
2.25%
2.05%
1.86%
2.11%
1.72%
1.75%
2.02%
2.04%
Employee Cost
-
906.44
746.69
622.81
558.83
472.85
306.76
247.00
193.79
168.46
149.21
% Of Sales
-
19.68%
18.98%
19.90%
17.83%
14.94%
14.92%
13.26%
12.75%
11.50%
12.41%
Manufacturing Exp.
-
368.41
269.25
244.53
289.79
209.91
263.38
272.44
191.95
183.83
145.34
% Of Sales
-
8.00%
6.84%
7.81%
9.24%
6.63%
12.81%
14.62%
12.63%
12.54%
12.09%
General & Admin Exp.
-
339.82
340.56
283.43
299.79
233.28
145.68
117.73
87.73
80.25
63.01
% Of Sales
-
7.38%
8.66%
9.05%
9.56%
7.37%
7.09%
6.32%
5.77%
5.48%
5.24%
Selling & Distn. Exp.
-
531.19
590.04
380.21
393.14
244.62
244.69
194.03
154.78
129.93
113.65
% Of Sales
-
11.53%
15.00%
12.15%
12.54%
7.73%
11.90%
10.41%
10.18%
8.87%
9.45%
Miscellaneous Exp.
-
104.05
50.48
28.03
26.58
117.38
17.26
15.86
7.27
20.11
113.65
% Of Sales
-
2.26%
1.28%
0.90%
0.85%
3.71%
0.84%
0.85%
0.48%
1.37%
2.43%
EBITDA
-
1,214.07
856.10
615.26
614.71
1,005.11
395.21
357.06
248.60
215.87
143.01
EBITDA Margin
-
26.36%
21.76%
19.66%
19.61%
31.75%
19.22%
19.16%
16.35%
14.73%
11.90%
Other Income
-
13.88
26.86
34.87
2.58
8.83
12.09
4.44
16.71
16.31
21.01
Interest
-
27.16
18.41
3.40
5.23
5.43
3.81
10.40
23.98
37.55
27.59
Depreciation
-
157.32
115.23
105.46
82.97
72.21
44.41
40.49
34.97
33.65
29.59
PBT
-
1,043.47
749.32
541.27
529.09
936.30
359.07
310.61
206.35
160.98
106.84
Tax
-
199.18
156.75
120.36
122.19
216.12
76.35
75.10
41.10
30.85
21.46
Tax Rate
-
19.92%
20.92%
22.24%
23.09%
23.08%
21.26%
24.18%
19.92%
19.16%
20.09%
PAT
-
828.76
593.65
420.72
406.99
720.18
282.72
235.51
165.25
130.13
85.39
PAT before Minority Interest
-
800.64
592.57
420.91
406.90
720.18
282.72
235.51
165.25
130.13
85.39
Minority Interest
-
28.12
1.08
-0.19
0.09
0.00
0.00
0.00
0.00
0.00
0.00
PAT Margin
-
17.99%
15.09%
13.44%
12.98%
22.75%
13.75%
12.64%
10.87%
8.88%
7.10%
PAT Growth
-
39.60%
41.10%
3.37%
-43.49%
154.73%
20.05%
42.52%
26.99%
52.39%
 
EPS
-
43.97
31.49
22.32
21.59
38.21
15.00
12.49
8.77
6.90
4.53

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Shareholder's Funds
3,219.40
2,718.82
2,220.14
1,902.33
1,597.36
884.64
675.57
502.94
395.00
296.73
Share Capital
37.70
37.70
37.70
37.70
37.70
37.70
37.70
37.70
37.70
11.00
Total Reserves
3,181.70
2,681.12
2,182.44
1,864.63
1,559.66
846.94
637.87
465.24
357.30
259.03
Non-Current Liabilities
1,046.98
570.08
576.20
94.15
84.02
72.44
94.32
103.25
122.07
150.80
Secured Loans
0.00
0.00
0.00
0.00
0.00
18.80
41.95
59.71
76.32
89.67
Unsecured Loans
886.99
499.30
500.00
0.00
0.00
0.00
10.27
10.83
18.54
38.81
Long Term Provisions
74.51
52.03
40.76
57.22
28.23
9.36
6.68
6.06
5.39
5.10
Current Liabilities
1,751.61
1,489.65
1,144.40
692.67
747.19
684.09
602.51
528.57
583.13
413.28
Trade Payables
625.93
702.32
759.32
500.73
565.65
324.94
288.44
239.96
209.15
138.57
Other Current Liabilities
226.98
322.20
142.89
81.28
51.80
44.56
60.62
69.25
151.60
84.90
Short Term Borrowings
860.50
429.13
207.78
88.51
113.71
219.70
25.42
70.11
138.43
146.28
Short Term Provisions
38.20
36.00
34.41
22.15
16.03
94.88
228.02
149.24
83.95
43.53
Total Liabilities
5,989.03
4,777.76
3,941.05
2,689.26
2,428.57
1,641.17
1,372.40
1,134.76
1,100.20
860.81
Net Block
1,551.84
1,158.45
993.38
799.40
708.09
546.87
396.96
344.22
267.82
271.99
Gross Block
2,132.41
1,522.57
1,242.47
950.09
1,093.63
861.06
665.08
572.48
462.91
433.54
Accumulated Depreciation
526.86
364.12
249.09
150.69
385.54
314.19
268.12
228.26
195.09
161.55
Non Current Assets
3,526.30
2,820.03
2,116.31
1,316.80
917.30
750.43
515.81
415.66
364.35
308.30
Capital Work in Progress
1,846.18
1,551.23
1,010.15
396.28
92.52
83.14
20.67
32.26
58.24
26.50
Non Current Investment
17.62
48.76
41.64
49.88
53.43
2.26
3.36
3.30
3.30
3.26
Long Term Loans & Adv.
110.66
61.59
71.14
71.24
29.96
118.15
94.82
35.88
34.99
6.54
Other Non Current Assets
0.00
0.00
0.00
0.00
33.30
0.00
0.00
0.00
0.00
0.00
Current Assets
2,462.73
1,957.73
1,824.74
1,372.46
1,511.27
890.74
856.59
719.10
735.85
552.51
Current Investments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Inventories
1,187.54
967.26
733.93
632.75
569.79
382.77
310.78
266.83
258.74
219.23
Sundry Debtors
864.75
488.89
526.34
338.82
350.48
361.17
273.37
232.87
199.33
201.97
Cash & Bank
80.74
205.62
89.92
159.60
450.83
26.83
23.96
16.11
47.09
6.29
Other Current Assets
329.70
18.24
27.49
7.56
140.17
119.98
248.48
203.29
230.68
125.02
Short Term Loans & Adv.
301.61
277.72
447.06
233.73
133.08
119.98
248.48
203.29
230.68
125.02
Net Current Assets
711.12
468.08
680.34
679.79
764.08
206.65
254.08
190.53
152.71
139.23
Total Assets
5,989.03
4,777.76
3,941.05
2,689.26
2,428.57
1,641.17
1,372.40
1,134.76
1,100.20
860.81

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Cash From Operating Activity
449.15
811.96
312.42
328.55
947.65
171.76
239.97
264.82
141.77
95.00
PBT
999.82
749.32
541.27
529.09
936.16
359.07
310.61
206.35
160.98
106.84
Adjustment
278.28
120.62
87.12
83.06
69.60
44.61
69.76
53.30
75.09
54.71
Changes in Working Capital
-592.84
108.52
-180.85
-165.64
138.90
-162.50
-71.53
43.86
-61.59
-48.76
Cash after chg. in Working capital
685.26
978.46
447.54
446.51
1,144.66
241.18
308.84
303.51
174.48
112.79
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-236.11
-166.50
-135.12
-117.96
-197.01
-69.42
-68.87
-38.70
-32.71
-17.80
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-731.64
-755.60
-884.38
-485.91
-306.80
-255.61
-81.06
-67.02
-56.39
-56.82
Net Fixed Assets
-789.71
-630.35
-606.86
-121.60
-288.80
-200.26
-81.01
-83.59
-61.11
Net Investments
-326.86
-215.85
-195.85
-65.58
-4.13
0.00
-29.98
0.00
0.00
Others
384.93
90.60
-81.67
-298.73
-13.87
-55.35
29.93
16.57
4.72
Cash from Financing Activity
154.85
59.04
502.63
-128.88
-224.30
86.72
-151.06
-228.78
-44.58
-46.95
Net Cash Inflow / Outflow
-127.64
115.40
-69.33
-286.24
416.55
2.86
7.86
-30.98
40.80
-8.77
Opening Cash & Equivalents
199.07
83.74
153.07
439.32
22.77
23.96
16.11
47.09
6.29
15.06
Closing Cash & Equivalent
71.84
199.07
83.74
153.08
439.32
26.83
23.96
16.11
47.09
6.29

Financial Ratios

Consolidated /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Book Value (Rs.)
170.79
144.23
117.78
100.92
84.74
46.93
35.84
26.68
20.95
49.10
ROA
14.87%
13.59%
12.70%
15.90%
35.39%
18.76%
18.79%
14.79%
13.27%
9.92%
ROE
26.97%
24.00%
20.42%
23.25%
58.03%
36.24%
39.97%
36.81%
39.14%
31.62%
ROCE
23.30%
22.66%
22.15%
28.87%
65.87%
37.54%
43.54%
32.05%
28.93%
21.52%
Fixed Asset Turnover
2.52
2.85
2.86
3.07
3.24
2.71
3.02
2.95
3.28
2.79
Receivable days
53.64
47.09
50.43
40.13
41.02
55.91
49.38
51.58
49.79
60.94
Inventory Days
85.38
78.91
79.67
70.01
54.91
61.11
56.34
62.73
59.30
66.15
Payable days
69.87
91.89
98.47
84.03
83.80
69.83
66.49
69.05
51.02
50.77
Cash Conversion Cycle
69.15
34.11
31.63
26.12
12.13
47.19
39.23
45.26
58.07
76.32
Total Debt/Equity
0.54
0.42
0.32
0.05
0.07
0.30
0.16
0.37
0.89
1.21
Interest Cover
37.81
41.70
160.20
102.16
173.43
95.30
30.87
9.60
5.29
4.87

Annual Reports:

FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015
FY 2014
FY 2013
FY 2012

News Update:


  • Alembic Pharmaceuticals gets USFDA’s approval for Doxycycline Hyclate Tablets
    1st Jul 2020, 10:51 AM

    Doxycycline Hyclate Tablets USP, 75 mg and 150 mg have an estimated market size of $17 million for twelve months ending March 2020

    Read More
  • Alembic Pharmaceuticals gets USFDA’s tentative approval for Rivaroxaban Tablets
    22nd Jun 2020, 10:48 AM

    Rivaroxaban Tablets, 10 mg, 15 mg, and 20 mg have an estimated market size of $6.1 billion for twelve months ending March 2020

    Read More
  • Alembic Pharmaceuticals gets EIR for general oral solid formulation facility at Panelav
    19th Jun 2020, 12:16 PM

    With this, EIR is in place for all the company’s manufacturing facilities for international markets

    Read More
  • Alembic Pharmaceuticals’ JV gets USFDA’s approval for Adapalene Gel
    19th Jun 2020, 11:23 AM

    Adapalene Gel USP, 0.3% is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older

    Read More
  • Alembic Pharmaceuticals gets USFDA’s final approval for Deferasirox Tablets
    16th Jun 2020, 11:10 AM

    Alembic now has a total of 122 ANDA approvals (109 final approvals and 13 tentative approvals) from USFDA

    Read More
  • Alembic Pharmaceuticals’ JV receives USFDA’s approval for Clobetasol Propionate Shampoo
    19th May 2020, 11:04 AM

    Alembic has a cumulative total of 122 ANDA approvals (109 final approvals and 13 tentative approvals) from USFDA

    Read More
  • Alembic Pharmaceuticals gets USFDA’s final approval for Doxycycline Hyclate Tablets
    15th May 2020, 13:19 PM

    The company has a cumulative total of 121 ANDA approvals from USFDA

    Read More
  • Alembic Pharmaceuticals’ JV gets EIR from USFDA for formulation facility at Gujarat
    6th May 2020, 11:54 AM

    The inspection was carried out by them at Aleor's Formulation Facility at Karakhadi, Gujarat, India during the period from January 6, 2020 to January 8, 2020

    Read More
  • Alembic Pharmaceuticals’ Panelav facility gets VAI from USFDA
    4th May 2020, 11:29 AM

    Inspection at the said Facility was conducted by USFDA from March 09, 2020 to March 13, 2020

    Read More
  • Alembic Pharmaceuticals gets USFDA’s tentative approval for Alcaftadine Ophthalmic Solution
    20th Apr 2020, 10:30 AM

    Alcaftadine Ophthalmic Solution is an H1 histamine receptor antagonist indicated for the prevention of itching associated with allergic conjunctivitis

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.